Talk here of Gilead’s interest in doing a deal with ARCUS. Shares jumped 51% with the news of that possibility.Is Gilead chief Dan O’Day ready for a new biotech deal in the oncology field?ARCUS also have drugs that are antagonists of adenosine receptors. Imugene has submitted a patent for increasing arginine availability in the tumour environment. Some studies report that arginine inhibits the expression of adenosine receptors.We haven’t had any update on the research being done by IMU on arginine. It would be nice to hear of any progress in that direction.
Is Gilead chief Dan O’Day ready for a new biotech deal in the oncology field?
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
0.003(6.82%) |
Mkt cap ! $349.6M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.9¢ | 4.5¢ | $963.9K | 20.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 1558493 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 1495843 | 7 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |